TreatSMA attends the International Scientific Congress on Spinal Muscular Atrophy

On 25–27 January, for three days in Kraków, Poland the SMA European Congress was held. With over 450 participants there were specialists, organisations to researchers and pharmaceutical companies from all over the world that attended and spoke. One room was dedicated to 80+ academic posters on SMA, one of which bore a TreatSMA logo as we had contributed to it. With over 40 talks ranging from newborn screening to standards of care to trial results and emerging drugs it was a packed full itinerary. This is now the largest SMA scientific event ever to be held, with a stunning Gala at the Salt Mine to add.

It is a very exciting time in the SMA community.

Look up the Congress website.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more